Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction
NCT04304560Phase 2Unknown
- Sponsor
- Damanhour University
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), diabetic cardiomyopathy (DCM), type 2 diabetes mellitus (T2DM), sponsored by Damanhour University. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)diabetic cardiomyopathy (DCM)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04304560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304560.